Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Mol Psychiatry. 2009 Dec 29;16(2):202–215. doi: 10.1038/mp.2009.125

Table 6.

Strongest meta-analysis findings for Narrow phenotype (All, Male or Female subjects)

R2 --GAIN-MDD-- --GenRED-- --STAR*D-- Meta-analysis
Band SNP BP A1/
A2
All
Frq
GAIN GR SD OR P OR P OR P OR P Annotation
ALL-NARROW

18q22.1 rs17077540 63436259 A/G 0.110 0.331 0.859 0.649 1.250 2.93E-01 1.610 1.83E-07 1.302 3.94E-02 1.481 6.04E-07 mRNA BC053410 (LOC643542);DSEL (up)
5p13.2 rs270592 38102343 A/G 0.570 0.996 0.989 0.991 1.170 3.62E-02 1.320 2.49E-06 1.150 3.56E-02 1.223 1.88E-06 GDNF (220kb up)
Xp21.1 rs2405829 32364267 A/G 0.540 0.960 0.960 0.960 1.280 5.50E-04 1.130 1.87E-02 1.190 2.10E-03 1.180 3.84E-06 DMD
6p22.1 rs6930508 27161121 C/T 0.560 0.988 0.999 0.999 1.240 5.41 E-03 1.180 4.19E-03 1.231 1.55E-03 1.213 4.73E-06 histone 2/4 gene cluster; GUSBL1 (up,noncoding)
10p11.23 rs1612122 29331904 A/T 0.480 0.959 0.953 0.923 1.280 1.48E-03 1.200 2.38E-03 1.176 1.78E-02 1.218 5.39E-06
3p26.1 rs9870680 7504555 C/T 0.433 0.847 1.000 1.000 1.287 1.97E-03 1.220 4.76E-04 1.134 5.13E-02 1.211 5.56E-06 GRM7
3q25.1 rs1456139 152123994 A/G 0.610 0.999 0.845 0.839 1.180 1.99E-02 1.240 9.11E-04 1.242 3.40E-03 1.219 7.92E-06 CLRN1 (dwn)
CRLF1; up:C19orf50,UBA52,C19orf60;
19p13.11 rs7249956 18576203 A/C 0.770 0.893 0.898 0.732 1.270 1.41E-02 1.260 1.69E-03 1.316 2.77E-03 1.277 8.11E-06 dwn:TMEM59L,KLHL26
12q23.3 rs1895943 106764962 A/C 0.040 0.989 1.000 0.803 1.350 6.85E-02 1.600 1.67E-04 1.602 4.03E-03 1.519 8.70E-06 CpG island at 106.76 Mb; PRDM4 (85kb up)
6q22.1 rs1855625 114535864 G/T 0.684 0.998 1.000 0.996 1.110 2.00E-01 1.283 9.00E-05 1.279 7.64E-04 1.226 9.34E-06 HS3ST5,−45130
1p32.2 rs6694643 57121995 A/T 0.120 0.990 1.000 0.885 1.510 7.88E-05 1.210 1.16E-02 1.189 8.94E-02 1.294 9.50E-06 C8A,within; C8B,45475

MALES-NARROW

3p14.1 rs11710109 66836364 C/T 0.380 0.990 0.991 0.843 1.580 2.46E-03 1.500 6.06E-05 1.397 2.70E-03 1.483 6.54E-08
11p15.1 rs389967 16831186 A/G 0.100 0.947 1.000 0.975 1.470 8.23E-02 1.710 2.33E-04 1.761 1.64E-04 1.675 5.75E-07 PLEKHA7,within
4q23 rs10007831 99911315 C/T 0.520 0.977 0.984 0.684 1.600 1.75E-03 1.340 3.39E-03 1.493 1.13E-03 1.441 9.64E-07
10q11.21 rs7079573 44720412 A/G 0.540 0.920 0.882 0.624 1.430 2.46E-02 1.380 2.42E-03 1.473 2.58E-03 1.418 9.53E-06 KSP37,−6357 check dir

FEMALES-NARROW

5p13.2 rs270584 38110611 A/C 0.560 0.999 1.000 1.000 1.200 3.47E-02 1.390 1.64E-05 1.421 1.53E-04 1.321 3.71E-07 GDNF (230kb up)
2q22.1 rs6711718 137123482 C/T 0.390 1.000 0.997 0.749 1.400 1.14E-04 1.200 7.23E-03 1.295 1.33E-02 1.293 1.71E-06
6q25.2 rs644377 153260377 A/T 0.420 1.000 1.000 1.000 1.280 5.08E-03 1.330 1.44E-04 1.256 1.13E-02 1.294 1.91E-06
4q28.1 rs2203374 128653784 C/G 0.790 0.801 0.814 0.770 1.390 1.36E-02 1.560 5.91E-05 1.400 1.20E-02 1.461 2.71E-06 INTU (120kb up)
12q14.1 rs7977950 60513443 C/T 0.120 0.994 1.000 0.991 1.230 9.52E-02 1.400 1.30E-03 1.824 1.01E-06 1.421 3.40E-06 FAM19A2,within
11q13.4 rs17133921 74712634 A/G 0.060 1.000 1.000 1.000 1.550 3.77E-03 1.550 3.47E-03 1.643 1.96E-03 1.571 5.29E-06 ARRB1,within
15q25.3 rs11634319 84224912 C/T 0.760 1.000 1.000 0.829 1.450 1.94E-03 1.340 1.98E-03 1.353 1.40E-02 1.385 5.67E-06 KLHL25 (86kb up)
4q34.3 rs346101 179841206 A/G 0.510 0.991 0.989 0.886 1.330 1.56E-03 1.160 5.59E-02 1.508 1.70E-05 1.289 6.01E-06

See Table 5 legend. The following regions also achieved P > 10−5 in the Broad analysis (Table 5): 3p26.1 (GRM7, All), 10p11.23 (All), 11p15.1 (PLEKHA7, males), 10q11.21 (Males) and 2q22.1 (Females).